Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 10 | 2005 | 285 | 0.710 |
Why?
|
| ErbB Receptors | 5 | 2005 | 239 | 0.520 |
Why?
|
| Insulin-Like Growth Factor II | 7 | 2005 | 52 | 0.350 |
Why?
|
| Receptors, Thromboxane | 8 | 1997 | 122 | 0.320 |
Why?
|
| Papillomaviridae | 3 | 2005 | 87 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 219 | 0.280 |
Why?
|
| Papillomavirus Infections | 2 | 2005 | 163 | 0.270 |
Why?
|
| Testosterone | 9 | 1997 | 96 | 0.270 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 5 | 2005 | 46 | 0.260 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2005 | 44 | 0.240 |
Why?
|
| Nicotine | 3 | 2005 | 350 | 0.220 |
Why?
|
| Androstane-3,17-diol | 2 | 1992 | 3 | 0.210 |
Why?
|
| Muscle, Smooth, Vascular | 5 | 1997 | 317 | 0.200 |
Why?
|
| Epidermal Growth Factor | 1 | 2000 | 95 | 0.180 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1999 | 15 | 0.170 |
Why?
|
| Progesterone | 2 | 1999 | 115 | 0.160 |
Why?
|
| Spermatozoa | 2 | 1998 | 75 | 0.160 |
Why?
|
| Saimiri | 1 | 1998 | 8 | 0.160 |
Why?
|
| Renal Dialysis | 1 | 1999 | 174 | 0.160 |
Why?
|
| Renal Insufficiency | 1 | 1999 | 121 | 0.150 |
Why?
|
| Platelet Activating Factor | 1 | 1998 | 34 | 0.150 |
Why?
|
| Blood Platelets | 3 | 1996 | 284 | 0.150 |
Why?
|
| Aorta | 6 | 1997 | 316 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor C | 2 | 2005 | 7 | 0.130 |
Why?
|
| Oncogene Proteins, Viral | 3 | 2005 | 21 | 0.130 |
Why?
|
| Biomarkers, Tumor | 3 | 2005 | 508 | 0.130 |
Why?
|
| Up-Regulation | 3 | 2005 | 682 | 0.100 |
Why?
|
| Fetal Blood | 1 | 1992 | 131 | 0.100 |
Why?
|
| Pregnancy | 2 | 1999 | 2334 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2005 | 624 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 1996 | 64 | 0.080 |
Why?
|
| Female | 18 | 2005 | 38021 | 0.080 |
Why?
|
| Estradiol | 4 | 1995 | 176 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2005 | 8 | 0.070 |
Why?
|
| Radioligand Assay | 5 | 1997 | 109 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 40 | 0.060 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2005 | 5 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 4 | 2000 | 852 | 0.060 |
Why?
|
| Androgens | 2 | 1997 | 41 | 0.060 |
Why?
|
| Papanicolaou Test | 1 | 2005 | 54 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2005 | 78 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2005 | 182 | 0.060 |
Why?
|
| Cervix Uteri | 2 | 2001 | 64 | 0.060 |
Why?
|
| Cell Division | 2 | 2003 | 541 | 0.060 |
Why?
|
| Humans | 19 | 2005 | 68549 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 1851 | 0.050 |
Why?
|
| Genital Neoplasms, Female | 1 | 2003 | 37 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 2 | 1995 | 52 | 0.050 |
Why?
|
| Dihydrotestosterone | 3 | 1997 | 13 | 0.050 |
Why?
|
| Rats | 7 | 1997 | 5300 | 0.040 |
Why?
|
| Cells, Cultured | 5 | 1997 | 2673 | 0.040 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 1996 | 9 | 0.040 |
Why?
|
| Obstetric Labor Complications | 1 | 1999 | 20 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 1996 | 15 | 0.040 |
Why?
|
| Androstenedione | 2 | 1996 | 7 | 0.040 |
Why?
|
| Radioimmunoassay | 2 | 1995 | 164 | 0.040 |
Why?
|
| Gestational Age | 1 | 1999 | 389 | 0.040 |
Why?
|
| Reproduction | 1 | 1998 | 48 | 0.040 |
Why?
|
| Muscle Contraction | 2 | 1996 | 210 | 0.040 |
Why?
|
| Animals | 9 | 1998 | 20880 | 0.040 |
Why?
|
| Sex Characteristics | 2 | 1997 | 295 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 700 | 0.040 |
Why?
|
| Seasons | 1 | 1998 | 129 | 0.040 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 2 | 1994 | 52 | 0.040 |
Why?
|
| Thromboxane A2 | 2 | 1994 | 88 | 0.040 |
Why?
|
| Androstadienes | 1 | 1996 | 41 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 2 | 1994 | 107 | 0.030 |
Why?
|
| Male | 11 | 1998 | 37283 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 4 | 1996 | 84 | 0.030 |
Why?
|
| Time Factors | 3 | 1999 | 4655 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2003 | 756 | 0.030 |
Why?
|
| Sperm Motility | 1 | 1995 | 41 | 0.030 |
Why?
|
| Castration | 1 | 1995 | 13 | 0.030 |
Why?
|
| Coronary Vessels | 2 | 1997 | 313 | 0.030 |
Why?
|
| Megakaryocytes | 1 | 1995 | 18 | 0.030 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 1992 | 17 | 0.030 |
Why?
|
| Propranolol | 1 | 1994 | 102 | 0.030 |
Why?
|
| Granulosa Cells | 1 | 1994 | 21 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1994 | 54 | 0.030 |
Why?
|
| Receptors, Prostaglandin | 1 | 1993 | 74 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2000 | 1549 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 659 | 0.030 |
Why?
|
| Steroids | 1 | 1994 | 84 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1992 | 58 | 0.030 |
Why?
|
| Labor, Obstetric | 1 | 1992 | 23 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 1 | 1992 | 43 | 0.030 |
Why?
|
| China | 1 | 1992 | 138 | 0.020 |
Why?
|
| Iodine Radioisotopes | 3 | 1996 | 119 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2003 | 282 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2003 | 507 | 0.020 |
Why?
|
| In Vitro Techniques | 3 | 1997 | 765 | 0.020 |
Why?
|
| Epithelial Cells | 2 | 2001 | 431 | 0.020 |
Why?
|
| Guinea Pigs | 2 | 1997 | 124 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2005 | 24 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds | 2 | 1995 | 29 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2005 | 237 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2005 | 122 | 0.020 |
Why?
|
| Drug Interactions | 2 | 1996 | 289 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2005 | 110 | 0.010 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 1994 | 41 | 0.010 |
Why?
|
| Nicotinic Agonists | 1 | 2005 | 111 | 0.010 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2003 | 42 | 0.010 |
Why?
|
| Kinetics | 2 | 1996 | 1047 | 0.010 |
Why?
|
| Folic Acid | 1 | 2003 | 121 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 799 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 444 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 2003 | 69 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 384 | 0.010 |
Why?
|
| Adult | 4 | 1995 | 21379 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 447 | 0.010 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2001 | 13 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 95 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 258 | 0.010 |
Why?
|
| Cell Line | 2 | 1996 | 1752 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 81 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 981 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1174 | 0.010 |
Why?
|
| Hypertension | 1 | 1989 | 1533 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1753 | 0.010 |
Why?
|
| Seminal Vesicles | 1 | 1997 | 7 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 1997 | 34 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 1996 | 45 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1997 | 254 | 0.010 |
Why?
|
| Flutamide | 1 | 1996 | 10 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1996 | 276 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 1996 | 45 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1996 | 220 | 0.010 |
Why?
|
| Carbazoles | 1 | 1996 | 46 | 0.010 |
Why?
|
| Indomethacin | 1 | 1996 | 107 | 0.010 |
Why?
|
| Binding Sites | 1 | 1997 | 631 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 2093 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 1995 | 59 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1994 | 25 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1994 | 48 | 0.010 |
Why?
|
| Lactates | 1 | 1994 | 29 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 1994 | 127 | 0.010 |
Why?
|
| 20-alpha-Dihydroprogesterone | 1 | 1994 | 1 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1994 | 81 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1994 | 532 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1994 | 29 | 0.010 |
Why?
|
| Prostaglandin H2 | 1 | 1993 | 16 | 0.010 |
Why?
|
| Azasteroids | 1 | 1993 | 4 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1993 | 31 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1993 | 50 | 0.010 |
Why?
|
| Prostaglandins H | 1 | 1993 | 32 | 0.010 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 1993 | 48 | 0.010 |
Why?
|
| Middle Aged | 1 | 1992 | 21119 | 0.010 |
Why?
|
| Perfusion | 1 | 1994 | 131 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 381 | 0.010 |
Why?
|
| Estrogens | 1 | 1994 | 173 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 7028 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1994 | 567 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 1040 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1995 | 689 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 1265 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1995 | 1745 | 0.010 |
Why?
|
| Calcium | 1 | 1993 | 929 | 0.010 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 1989 | 9 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1989 | 31 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 1989 | 29 | 0.010 |
Why?
|
| Prolactin | 1 | 1989 | 61 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 2083 | 0.010 |
Why?
|
| Smoking | 1 | 1995 | 1449 | 0.000 |
Why?
|